ArticleThe oncologist2025
Contributing effects of sarcopenia on cancer occurrence: novel evidence based on NHANES 1999-2020 and two-sample mendelian randomization study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Variable selection-combined causal mediation analysis for continuous treatments with application to large-dimensional biomedical data.PLoS computational biology · 2026Article
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSarcopenia is associated with worse prognosis in patients with cancer, and patients with cancer usually have poor muscle condition. However, it is still not clear whether sarcopenia contributes to cancer occurrence.
methodsThis study utilized data from the National Health and Nutrition Examination Survey (NHANES) 1999-2020 to assess the relationship between sarcopenia and cancer. Key sarcopenia indicators, including lean mass measurements and sarcopenia diagnosed by European Working Group on Sarcopenia in Older People (EWGSOP) or Foundation for the National Institutes of Health (FNIH) criteria, were analyzed using quantile logistic regression models. A two-sample Mendelian Randomization (MR) approach was employed to explore the causal link between sarcopenia and cancer, leveraging genetic variants as instrumental variables.
resultsWe found that after adjusting covariates, left arm lean mass, left leg lean mass and appendicular lean mass (ALM) were found to have significant negative influences on the occurrence of overall-cancer types, particularly in individuals over 40 years old. Sarcopenia (FNIH) significantly increased the risk of overall-cancer types, especially colon, ovarian, and uterine cancers. Smooth curve fitting showed that cancer incidence decreased with increasing muscle mass. MR analysis confirmed that ALM and whole body lean mass (WBLM) had causally negative effects on cancer, while grip strength and sarcopenia (by EWGSOP/FNIH criteria) demonstrated significant causal effects on specific cancer types, including lymphoid hematopoietic cancer, lymphoid leukemia, and breast cancer.
conclusionSarcopenia significantly impacts the incidence of various cancers and may causally contribute to cancer development. Managing sarcopenia could potentially benefit cancer prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.